14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VOR vs PGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PGEN Overall Winner
6-Pillar Tally: VOR 1 – 5 PGEN
Matrix Metrics: VOR 3 – 7 PGEN
As of Nov 16, 2026, Precigen, Inc. (PGEN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin), whereas PGEN carries 60.2/100 (BUY) at $4.33 (7.3x Forward P/E, 21.4% operating margin).
Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile PGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs PGEN. Trailing 12-month operating profitability (VOR 0.0% vs PGEN 21.4%) and valuation multiples (VOR N/M vs PGEN 7.3x Forward P/E) are benchmarked directly in Pillar 4 below.
VOR Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
PGEN Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 21.4% operating margin.
OpEx & R&D Reinvestment53.1% of Rev ($135M)
90D Engineering Disclosures0 Published
Investor FAQ VOR vs PGEN Key Questions & Quantitative Answers
As of Nov 16, 2026, Precigen, Inc. (PGEN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin), whereas PGEN carries 60.2/100 (BUY) at $4.33 (7.3x Forward P/E, 21.4% operating margin). Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile PGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PGEN leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PGEN at +2437.6% YoY revenue growth and +0.0% YoY earnings growth on $254M TTM revenue (74.5% gross margin, 21.4% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $254M for PGEN. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus 53.1% of Rev ($135M) (0 disclosures) for PGEN.
PGEN screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PGEN trades at 7.3x Forward P/E, 42.4x Trailing P/E, N/M PEG, and 7.1x EV/Revenue (-47.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus PGEN (38.8% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk). By comparison, PGEN carries 84.8% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 122% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.